Examining Medicare Part D Cancer Drug Denials: Study Insights

A recent study published in JAMA Network Open sheds light on the complexities surrounding Medicare Part D cancer drug denials. It found that nearly 20% of second-level appeals were overturned upon review by an independent Medicare-contracted evaluator. Youngmin Kwon, PhD, from Vanderbilt University Medical Center, noted the ideal scenario would see a much lower overturn rate, reflecting consistently accurate initial denial decisions.

The analysis highlighted that appeals involving FDA-approved drug indications had a significantly higher overturn rate of approximately 60%, compared to about 17% for off-label uses. This variance reveals potential issues in initial decisions, as appropriate treatments may have been incorrectly rejected. The study examined 4,952 second-level appeals submitted between 2020 and 2024, and recognizes targeted therapies, hormonal therapies, and immunotherapies as key areas of focus.

Findings further show that 69% of rejected second-level appeals involved off-label drugs, often due to clerical errors, which accounted for 72% of these unsuccessful attempts. Successful appeals frequently relied on evidence from Medicare-approved drug compendia or peer-reviewed studies. Despite recent reforms in utilization management, experts suggest further standardization of coverage criteria to ensure that clinically beneficial treatments are not denied. The study, partially funded by the Agency for Healthcare Research and Quality and the National Cancer Institute, emphasizes refining appeals processes to better accommodate clinically appropriate cancer therapies.